Alberto Bardelli, Bs

List of Publications by Year in Descending Order

247 papers	44,524 citations	90 h-index	210 g-index
272 ext. papers	51,584 ext. citations	13.1 avg, IF	7.26 L-index

#	Paper	IF	Citations
247	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. *Cancer Discovery*, **2021**, 11, 1844-1859	24.4	11
246	EGFR Amplification in Metastatic Colorectal Cancer. *Journal of the National Cancer Institute*, **2021**, 113, 1561-1569	9.7	3
245	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. *Seminars in Cancer Biology*, **2021**,	12.7	1
244	Werner Helicase Is a Synthetic-Lethal Vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy, and Immunotherapy. *Cancer Discovery*, **2021**, 11, 1923-1937	24.4	10
243	Precision oncology in metastatic colorectal cancer - from biology to medicine. *Nature Reviews Clinical Oncology*, **2021**, 18, 506-525	19.4	27
242	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.. *Journal of Clinical Oncology*, **2021**, 39, 3506-3506	2.2	21
241	Clonally expanded EOMES Tr1-like cells in primary and metastatic tumors are associated with disease progression. *Nature Immunology*, **2021**, 22, 735-745	19.1	10
240	Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. *Cancer Discovery*, **2021**, 11, 1886-1895	24.4	1
239	Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. *Cancers*, **2021**, 13,	6.6	6
238	T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models. *Cancer Immunology Research*, **2021**, 9, 825-837	12.5	1
237	The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. *Cell Reports*, **2021**, 35, 109252	10.6	8
236	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. *JCO Precision Oncology*, **2021**, 5,	3.6	1
235	TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors. *Cancer Discovery* , **2021**, 11, 126-141	24.4	15
234	Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. *Cancers*, **2021**, 13,	6.6	1
233	Liquid biopsies for residual disease and recurrence.. *Med*, **2021**, 2, 1292-1313	31.7	1
232	RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. *Cell Death and Disease*, **2020**, 11, 930	9.8	8
231	EGFR Blockade Reverts Resistance to KRAS Inhibition in Colorectal Cancer. *Cancer Discovery*, **2020**, 10, 1129-1139	24.4	100

230	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2020**, 40, e292-e308	7.1	2
229	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. *Cancers*, **2020**, 12,	6.6	21
228	Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. *European Radiology*, **2020**, 30, 4496-4503	8	3
227	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2020**, 19, 256-262.e2	3.8	22
226	High-dose vitamin C enhances cancer immunotherapy. *Science Translational Medicine*, **2020**, 12,	17.5	65
225	Two main mutational processes operate in the absence of DNA mismatch repair. *DNA Repair*, **2020**, 89, 102827	4.3	10
224	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. *Journal of Clinical Oncology*, **2020**, 38, TPS4124-TPS4124	2.2	6
223	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. *Clinical Cancer Research*, **2020**, 26, 1372-1384	12.9	38
222	TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations. *Clinical Cancer Research*, **2020**, 26, 1624-1632	12.9	47
221	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. *ESMO Open*, **2020**, 5, e000911	6	35
220	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. *Annals of Oncology*, **2020**, 31, 1135-1147	10.3	27
219	Towards a cancer mission in Horizon Europe: recommendations. *Molecular Oncology*, **2020**, 14, 1589-1615	7.9	15
218	Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. *Cancer Treatment Reviews*, **2020**, 91, 102112	14.4	8
217	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. *Nature Medicine*, **2019**, 25, 1415-1421	50.5	161
216	Exploiting DNA repair defects in colorectal cancer. *Molecular Oncology*, **2019**, 13, 681-700	7.9	53
215	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. *Cancer Discovery*, **2019**, 9, 1064-1079	24.4	154
214	A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. *Clinical Colorectal Cancer*, **2019**, 18, 91-101.e3	3.8	15
213	Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours. *Neuropathology and Applied Neurobiology*, **2019**, 45, 655-670	5.2	6

212	Does early metastatic seeding occur in colorectal cancer?. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 651-653	24.2	4
211	How liquid biopsies can change clinical practice in oncology. *Annals of Oncology*, **2019**, 30, 1580-1590	10.3	107
210	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. *Clinical Cancer Research*, **2019**, 25, 6243-6259	12.9	25
209	High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. *Frontiers in Oncology*, **2019**, 9, 622	5.3	17
208	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. *Genome Medicine*, **2019**, 11, 42	14.4	19
207	Adaptive mutability of colorectal cancers in response to targeted therapies. *Science*, **2019**, 366, 1473-1480	39.3	148
206	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. *Journal of Clinical Oncology*, **2019**, 37, TPS2659-TPS2659	2.3	8
205	Plasma HER2 () Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2019**, 25, 3046-3053	12.9	58
204	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. *Oncologist*, **2019**, 24, 1395-1402	5.7	45
203	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. *ESMO Open*, **2019**, 4,	6	12
202	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. *Clinical Cancer Research*, **2019**, 25, 989-999	12.9	213
201	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. *Cancer Treatment Reviews*, **2019**, 73, 41-53	14.4	44
200	Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. *Annals of Oncology*, **2019**, 30, 211-218	10.3	51
199	Early-onset colorectal cancer in young individuals. *Molecular Oncology*, **2019**, 13, 109-131	7.9	173
198	Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. *Annals of Oncology*, **2018**, 29, 1108-1119	10.3	101
197	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. *ESMO Open*, **2018**, 3, e000299	6	24
196	Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, e175245	13.4	54
195	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. *Annals of Oncology*, **2018**, 29, 1394-1401	10.3	47

194	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. *Annals of Oncology*, **2018**, 29, 119-126	10.3	46
193	Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers. *Pathobiology*, **2018**, 85, 146-154	3.6	23
192	Preclinical models for precision oncology. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1870, 239-246	11.2	22
191	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. *Cancer Cell*, **2018**, 34, 148-162.e7	24.3	77
190	Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer. *Oncogene*, **2018**, 37, 4599-4610	9.2	23
189	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. *Nature Communications*, **2018**, 9, 2287	17.4	14
188	Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. *Gut*, **2018**, 67, 1995-2005	19.2	119
187	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. *Clinical Colorectal Cancer*, **2018**, 17, 80-83	3.8	34
186	Inactivation of DNA repair-prospects for boosting cancer immune surveillance. *Genome Medicine*, **2018**, 10, 91	14.4	4
185	The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. *Cancer Discovery*, **2018**, 8, 1518-1528	24.4	51
184	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. *Lancet Oncology, The*, **2018**, 19, 1360-1371	21.7	38
183	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo. *Nature Medicine*, **2018**, 24, 961-967	50.5	158
182	Exploring the links between cancer and placenta development. *Open Biology*, **2018**, 8,	7	52
181	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. *Clinical Cancer Research*, **2017**, 23, 3657-3666	12.9	44
180	Integrating liquid biopsies into the management of cancer. *Nature Reviews Clinical Oncology*, **2017**, 14, 531-548	19.4	970
179	Liquid Biopsies, What We Do Not Know (Yet). *Cancer Cell*, **2017**, 31, 172-179	24.3	288
178	Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. *Nature Communications*, **2017**, 8, 15617	17.4	25
177	Medical research: Personalized test tracks cancer relapse. *Nature*, **2017**, 545, 417-418	50.4	9

176	ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	126
175	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. *Nature Reviews Clinical Oncology*, **2017**, 14, 562-576	19.4	102
174	Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. *Annals of Oncology*, **2017**, 28, 1302-1308	10.3	23
173	Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions. *EMBO Molecular Medicine*, **2017**, 9, 293-303	12	39
172	Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. *Clinical Cancer Research*, **2017**, 23, 4312-4322	12.9	27
171	Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. *European Journal of Cancer*, **2017**, 71, 43-50	7.5	22
170	Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. *Cold Spring Harbor Perspectives in Medicine*, **2017**, 7,	5.4	6
169	Polyclonal Secondary Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. *Cancer Discovery*, **2017**, 7, 252-263	24.4	262
168	Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members. *Cancer Letters*, **2017**, 389, 59-69	9.9	20
167	Tumor Evolution as a Therapeutic Target. *Cancer Discovery*, **2017**,	24.4	108
166	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. *Nature*, **2017**, 552, 116-120	50.4	290
165	Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. *ESMO Open*, **2017**, 2, e000253	6	40
164	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. *British Journal of Cancer*, **2017**, 117, 347-352	8.7	22
163	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. *Clinical Cancer Research*, **2017**, 23, 2414-2422	12.9	111
162	Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	11
161	Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. *Cancer Treatment Reviews*, **2016**, 51, 54-62	14.4	19
160	Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. *Cancer Research*, **2016**, 76, 7181-7193	10.1	73
159	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. *Cancer Discovery*, **2016**, 6, 963-71	24.4	71

158	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. *Cancer Research*, **2016**, 76, 4504-15	10.1	63
157	Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients. *Molecular Oncology*, **2016**, 10, 475-80	7.9	43
156	The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer. *Clinical Cancer Research*, **2016**, 22, 3260-7	12.9	48
155	MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. *Science Translational Medicine*, **2016**, 8, 324ra14	17.5	61
154	Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. *Nature Medicine*, **2016**, 22, 262-9	50.5	533
153	Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. *Annals of Oncology*, **2016**, 27, 1062-1067	10.3	28
152	Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. *Cancer Discovery*, **2016**, 6, 147-153	24.4	255
151	Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. *Cancer Discovery*, **2016**, 6, 36-44	24.4	200
150	Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	94
149	HER2 amplification as a molecular bait for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial.. *Journal of Clinical Oncology*, **2016**, 34, TPS774-TPS774	2.2	16
148	Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds. *Oncotarget*, **2016**, 7, 58743-58758	3.3	26
147	CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. *PLoS ONE*, **2016**, 11, e0149099	3.7	47
146	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. *Annals of Oncology*, **2016**, 27, 1386-422	10.3	1683
145	Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. *Nature Communications*, **2016**, 7, 13665	17.4	121
144	Clonal evolution and - coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. *ESMO Open*, **2016**, 1, e000079	6	2
143	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. *Annals of Oncology*, **2016**, 27, 1443-8	10.3	53
142	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. *Cell*, **2016**, 165, 317-30	56.2	57
141	The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. *Nature Medicine*, **2016**, 22, 624-31	50.5	145

140	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. *Lancet Oncology, The*, **2016**, 17, 738-746	21.7	533
139	Toward understanding and exploiting tumor heterogeneity. *Nature Medicine*, **2015**, 21, 846-53	50.5	441
138	Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. *Annals of Oncology*, **2015**, 26, 1994-1999	10.3	93
137	The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. *Nature Communications*, **2015**, 6, 7002	17.4	178
136	Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. *Cancer Discovery*, **2015**, 5, 1271-81	24.4	126
135	Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. *Nature Communications*, **2015**, 6, 8305	17.4	80
134	Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. *FASEB Journal*, **2015**, 29, 464-76	0.9	35
133	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. *Nature Medicine*, **2015**, 21, 795-801	50.5	557
132	PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. *Cell Reports*, **2015**, 12, 1978-85	10.6	117
131	Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. *Clinical Cancer Research*, **2015**, 21, 2157-66	12.9	173
130	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. *Journal of Clinical Oncology*, **2015**, 33, TPS3632-TPS3632	2.2	3
129	Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. *Oncotarget*, **2015**, 6, 10994-1008	3.3	12
128	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. *Nature*, **2014**, 508, 118-22	50.4	550
127	Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. *Cancer Treatment Reviews*, **2014**, 40, 648-55	14.4	88
126	Minimal residual disease in breast cancer: in blood veritas. *Clinical Cancer Research*, **2014**, 20, 2505-7	12.9	14
125	Liquid biopsies: genotyping circulating tumor DNA. *Journal of Clinical Oncology*, **2014**, 32, 579-86	2.2	1419
124	Circulating pEGFR is a candidate response biomarker of cetuximab therapy in colorectal cancer. *Clinical Cancer Research*, **2014**, 20, 6346-56	12.9	21
123	Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. *Genome Biology*, **2014**, 15, 449	18.3	63

122	The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. *Neuro-Oncology*, **2014**, 16, 1263-73	1	123
121	Somatic alterations as the basis for resistance to targeted therapies. *Journal of Pathology*, **2014**, 232, 244-54	9.4	27
120	Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. *Cancer Discovery*, **2014**, 4, 1269-80	24.4	326
119	TGF and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. *Clinical Cancer Research*, **2014**, 20, 6429-38	12.9	80
118	Climbing RAS, the everest of oncogenes. *Cancer Discovery*, **2014**, 4, 19-21	24.4	18
117	Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. *Cell Reports*, **2014**, 7, 86-93	10.6	207
116	Detection of circulating tumor DNA in early- and late-stage human malignancies. *Science Translational Medicine*, **2014**, 6, 224ra24	17.5	2741
115	RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. *Cell Reports*, **2014**, 8, 1475-83	8.6	89
114	Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. *Human Mutation*, **2014**, 35, 208-14	4.7	13
113	Mutational profiling of kinases in glioblastoma. *BMC Cancer*, **2014**, 14, 718	4.8	39
112	Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. *Science Translational Medicine*, **2014**, 6, 224ra26	17.5	203
111	Acquired resistance to EGFR-targeted therapies in colorectal cancer. *Molecular Oncology*, **2014**, 8, 1084-94	7.9	94
110	Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients avatars.. *Journal of Clinical Oncology*, **2014**, 32, 2626-2626	2.2	3
109	Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?. *Cellular and Molecular Life Sciences*, **2013**, 70, 4131-40	10.3	16
108	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. *International Journal of Cancer*, **2013**, 133, 1259-65	7.5	141
107	Liquid biopsy: monitoring cancer-genetics in the blood. *Nature Reviews Clinical Oncology*, **2013**, 10, 472-84	19.4	1134
106	Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. *Human Mutation*, **2013**, 34, 330-7	4.7	4
105	Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discovery*, **2013**, 3, 658-73	24.4	489

104	Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET. *Clinical Cancer Research*, **2013**, 19, 2381-92	12.9	139
103	BRAF V600E is a determinant of sensitivity to proteasome inhibitors. *Molecular Cancer Therapeutics* , **2013**, 12, 2950-61	6.1	14
102	Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. *Cancer Research*, **2013**, 73, 1912-21	10.1	14
101	Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing?. *Clinical Cancer Research*, **2013**, 19, 2794-6	12.9	2
100	Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification).. *Journal of Clinical Oncology*, **2013**, 31, TPS3648-TPS3648	2.2	7
99	Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes. *PLoS ONE*, **2012**, 7, e36402	3.7	39
98	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. *Nature*, **2012**, 483, 100-3	50.4	1417
97	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. *Nature*, **2012**, 486, 532-6	50.4	1327
96	Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. *Clinical Cancer Research*, **2012**, 18, 2515-25	12.9	152
95	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E353-9	11.5	42
94	Activation of □catenin by oncogenic PIK3CA and EGFR promotes resistance to glucose deprivation by inducing a strong antioxidant response. *PLoS ONE*, **2012**, 7, e37526	3.7	7
93	Targeted therapies: how personal should we go?. *Nature Reviews Clinical Oncology*, **2011**, 9, 87-97	19.4	87
92	A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. *Cancer Discovery*, **2011**, 1, 508-23	24.4	668
91	MET mutations in cancers of unknown primary origin (CUPs). *Human Mutation*, **2011**, 32, 44-50	4.7	57
90	Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. *Clinical Cancer Research*, **2011**, 17, 6531-41	12.9	42
89	Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. *Clinical Cancer Research*, **2011**, 17, 4901-14	12.9	143
88	Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects. *Leukemia and Lymphoma*, **2011**, 52, 1742-50	1.9	13
87	Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). *Annals of Oncology*, **2011**, 22, 2424-2430	10.3	47

86	KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. *PLoS ONE*, **2011**, 6, e29146	3.7	26
85	International network of cancer genome projects. *Nature*, **2010**, 464, 993-8	50.4	1613
84	Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas. *PLoS ONE*, **2010**, 5, e12653	3.7	11
83	Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. *JAMA - Journal of the American Medical Association*, **2010**, 304, 1812-20	27.4	580
82	PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 10208-13	11.5	293
81	Reply to E. Hawkes et al. *Journal of Clinical Oncology*, **2010**, 28, e532-e533	2.2	1
80	Broccoli, PTEN deletion and prostate cancer: where is the link?. *Molecular Cancer*, **2010**, 9, 308	42.1	5
79	Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. *Journal of Clinical Oncology*, **2010**, 28, 1254-61	2.2	582
78	Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. *Cancer Treatment Reviews*, **2010**, 36 Suppl 3, S1-5	14.4	32
77	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncology, The*, **2010**, 11, 753-62	21.7	1653
76	The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. *Journal of Experimental and Clinical Cancer Research*, **2010**, 29, 32	12.8	48
75	Tracking the genomic evolution of breast cancer metastasis. *Breast Cancer Research*, **2010**, 12, 302	8.3	
74	The prognostic IDH1(R132) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. *Acta Neuropathologica*, **2010**, 119, 487-94	14.3	224
73	Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. *Targeted Oncology*, **2010**, 5, 19-28	5	26
72	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. *BMC Cancer*, **2010**, 10, 631	4.8	128
71	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. *Journal of Clinical Investigation*, **2010**, 120, 2858-66	15.9	282
70	Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. *Current Opinion in Molecular Therapeutics*, **2010**, 12, 703-11		
69	Recommendations for mutational analysis of EGFR in lung carcinoma. *Pathologica*, **2010**, 102, 119-26	1.9	30

68	Mutational profile of GNAQQ209 in human tumors. *PLoS ONE*, **2009**, 4, e6833	3.7	57
67	Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. *PLoS ONE*, **2009**, 4, e7287	3.7	209
66	Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. *Human Mutation*, **2009**, 30, E451-9	4.7	37
65	IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. *Human Mutation*, **2009**, 30, 7-11	4.7	320
64	Molecular profiling of the "plexinome" in melanoma and pancreatic cancer. *Human Mutation*, **2009**, 30, 1167-74	4.7	34
63	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). *British Journal of Cancer*, **2009**, 101, 1261-8	8.7	121
62	Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). *Biochemical and Biophysical Research Communications*, **2009**, 386, 593-7	3.4	32
61	PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. *Cancer Research*, **2009**, 69, 1851-7	10.1	642
60	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *Journal of the National Cancer Institute*, **2009**, 101, 1308-24	9.7	424
59	Expression and functional regulation of myoglobin in epithelial cancers. *American Journal of Pathology*, **2009**, 175, 201-6	5.8	57
58	Absence of AKT1 mutations in glioblastoma. *PLoS ONE*, **2009**, 4, e5638	3.7	14
57	AKT1(E17K) in human solid tumours. *Oncogene*, **2008**, 27, 5648-50	9.2	165
56	PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. *Breast Cancer Research*, **2008**, 10, R27	8.3	43
55	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. *Journal of Clinical Oncology*, **2008**, 26, 5705-12	2.2	1358
54	Understanding how kinase-targeted therapies work. *Cell Cycle*, **2008**, 7, 1560-3	4.7	2
53	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 20864-9	11.5	79
52	PIK3CA cancer mutations display gender and tissue specificity patterns. *Human Mutation*, **2008**, 29, 284-8	4.7	107
51	Genetic targeting of the kinase activity of the Met receptor in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 11412-7	11.5	35

50	Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. *Cancer Research*, **2007**, 67, 8468-76	10.1	28
49	Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. *Cancer Research*, **2007**, 67, 3545-50	10.1	136
48	Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. *Cancer Research*, **2007**, 67, 7088-94	10.1	25
47	Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. *Cancer Research*, **2007**, 67, 2643-8	10.1	708
46	Kinase mutations in cancer: chinks in the enemy's armour?. *Current Opinion in Oncology*, **2006**, 18, 69-76	4.2	6
45	Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. *Lancet Oncology, The*, **2005**, 6, 279-86	21.7	833
44	Mutational analysis of gene families in human cancer. *Current Opinion in Genetics and Development*, **2005**, 15, 5-12	4.9	40
43	Identification of cancer genes by mutational profiling of tumor genomes. *FEBS Letters*, **2005**, 579, 1884-90	3.8	20
42	Colorectal cancer: mutations in a signalling pathway. *Nature*, **2005**, 436, 792	50.4	452
41	Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells. *Molecular Cancer Therapeutics*, **2005**, 4, 1026-30	6.1	9
40	PRL-3 phosphatase is implicated in ovarian cancer growth. *Clinical Cancer Research*, **2005**, 11, 6835-9	12.9	119
39	Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. *Cancer Research*, **2005**, 65, 11227	10.1	42
38	Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. *Annals of Oncology*, **2005**, 16, 1848-9	10.3	23
37	Alterations in vascular gene expression in invasive breast carcinoma. *Cancer Research*, **2004**, 64, 7857-66	10.1	165
36	Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. *Cancer Research*, **2004**, 64, 8816-20	10.1	404
35	Mutational analysis of the tyrosine phosphatome in colorectal cancers. *Science*, **2004**, 304, 1164-6	33.3	431
34	p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. *Cancer Biology and Therapy*, **2004**, 3, 221-5	4.6	42
33	SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 16897-902	11.5	62

32	Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 3089-94	11.5	163
31	High frequency of mutations of the PIK3CA gene in human cancers. *Science*, **2004**, 304, 554	33.3	2657
30	PRL-3: a phosphatase for metastasis?. *Cancer Biology and Therapy*, **2004**, 3, 952-3	4.6	23
29	Mutational analysis of the tyrosine kinome in colorectal cancers. *Science*, **2003**, 300, 949	33.3	392
28	Identifying tumor origin using a gene expression-based classification map. *Cancer Research*, **2003**, 63, 4144-9	10.1	72
27	PRL-3 expression in metastatic cancers. *Clinical Cancer Research*, **2003**, 9, 5607-15	12.9	133
26	Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. *Nature*, **2002**, 418, 934	50.4	962
25	A phosphatase associated with metastasis of colorectal cancer. *Science*, **2001**, 294, 1343-6	33.3	539
24	Carcinogen-specific induction of genetic instability. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 5770-5	11.5	140
23	Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. *Current Drug Targets*, **2001**, 2, 41-55	3	55
22	Different point mutations in the met oncogene elicit distinct biological properties. *FASEB Journal*, **2000**, 14, 399-406	0.9	87
21	A peptide representing the carboxyl-terminal tail of the met receptor inhibits kinase activity and invasive growth. *Journal of Biological Chemistry*, **1999**, 274, 29274-81	5.4	50
20	Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. *Oncogene*, **1999**, 18, 1139-46	9.2	69
19	Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. *Oncogene*, **1999**, 18, 4275-81	9.2	52
18	Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. *Oncogene*, **1999**, 18, 5221-31	9.2	129
17	MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential. *Journal of Cellular Physiology*, **1999**, 181, 507-14	7	22
16	Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. *International Journal of Cancer*, **1999**, 82, 640-3	7.5	70
15	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. *Nature*, **1998**, 391, 285-8	50.4	447

14	Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 14379-83	11.5	86
13	Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. *Biochemical Journal*, **1998**, 336 (Pt 1), 235-9	3.8	28
12	A point mutation in the MET oncogene abrogates metastasis without affecting transformation. *Proceedings of the National Academy of Sciences of the United States of America*, **1997**, 94, 13868-72	11.5	82
11	Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. *Oncogene*, **1997**, 14, 705-11	9.2	46
10	Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential. *Oncogene*, **1997**, 15, 3103-11	9.2	116
9	"Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **1997**, 1333, M41-51	11.2	20
8	Scatter factor receptors are key players in a unique multistep program leading to invasive growth. *Novartis Foundation Symposium*, **1997**, 212, 133-44; discussion 144-7		6
7	The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. *Molecular and Cellular Biology*, **1996**, 16, 2151-63	4.8	164
6	Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. *Journal of Biological Chemistry*, **1996**, 271, 14119-23	5.4	121
5	Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. *Journal of Biological Chemistry*, **1995**, 270, 603-11	5.4	201
4	A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. *Cell*, **1994**, 77, 261-71	56.2	907
3	Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. *Journal of Biotechnology*, **1994**, 37, 109-22	3.7	42
2	A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor. *Molecular and Cellular Biology*, **1993**, 13, 4600-8	4.8	175
1	Evolving neoantigen profiles in colorectal cancers with DNA repair defects		1